id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-290256-mkfg7nar	Ren, Zhigang	A Randomized, Open‐label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, A Pilot Study	2020-07-14		.txt	text/plain	4625	232	55	Patients meeting the following criteria were enrolled in the study: 1) age 18 and over, regardless of gender; 2) respiratory or blood samples that were tested positive for SARS-CoV-2 nucleic acid by real-time reverse transcriptase polymerase chain reaction (RT-PCR), or respiratory or blood samples that were tested highly homologous with the known SARS-CoV-2 by viral gene sequencing; 3) the confimation of COVID-19 according to the diagnostic criteria of "the latest Clinical guidelines for novel coronavirus" issued by the World Health Organization (WHO) on January 28, 2020, and the diagnostic criteria from the "Diagnosis and treatment program trial version 5 (or 6) guidelines" issued by the National Health Commission of the People's Republic of China. According to the Diagnosis and treatment program trial version 5 guidelines, the criteria for release and discharge were as follows: body temperature returned to normal for more than 3 days, respiratory symptoms showing obvious improvement, pulmonary imaging showing that the inflammation was obviously absorbed, and negative respiratory pathogenic nucleic acid testing for two consecutive assessments (with a sampling interval of at least 1 day).	./cache/cord-290256-mkfg7nar.txt	./txt/cord-290256-mkfg7nar.txt